{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:23:20Z","timestamp":1770978200670,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["305321"],"award-info":[{"award-number":["305321"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EO1003"],"award-info":[{"award-number":["01EO1003"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-1861-3","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T08:53:18Z","timestamp":1489654398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II\/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma \u2013 the STRONG study: study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-7396","authenticated-orcid":false,"given":"Katrin","family":"Lorenz","sequence":"first","affiliation":[]},{"given":"Yvonne","family":"Scheller","sequence":"additional","affiliation":[]},{"given":"Katharina","family":"Bell","sequence":"additional","affiliation":[]},{"given":"Franz","family":"Grus","sequence":"additional","affiliation":[]},{"given":"Katharina A.","family":"Ponto","sequence":"additional","affiliation":[]},{"given":"Felix","family":"Bock","sequence":"additional","affiliation":[]},{"given":"Claus","family":"Cursiefen","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Flach","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Gehring","sequence":"additional","affiliation":[]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[]},{"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Yossi","family":"Tal","sequence":"additional","affiliation":[]},{"given":"Norbert","family":"Pfeiffer","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"1861_CR1","unstructured":"Harasymowycz P. Anti-VEGF therapy and neovascular glaucoma. Glaucoma Today. 2012."},{"issue":"5","key":"1861_CR2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0161-6420(83)34542-5","volume":"90","author":"SS Hayreh","year":"1983","unstructured":"Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90(5):488\u2013506.","journal-title":"Ophthalmology"},{"key":"1861_CR3","doi-asserted-by":"crossref","unstructured":"Kimoto K, Kubota T. Anti-VEGF agents for ocular angiogenesis and vascular permeability. J Ophthalmol. 2012;2012:1\u201311. Article ID 852183.","DOI":"10.1155\/2012\/852183"},{"issue":"5","key":"1861_CR4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ico.0000220776.93852.d9","volume":"25","author":"JH Tsai","year":"2006","unstructured":"Tsai JH, Derby E, Holland EJ, Khatana AK. Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea. 2006;25(5):530\u20132.","journal-title":"Cornea"},{"issue":"12","key":"1861_CR5","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","volume":"120","author":"SR Boyd","year":"2002","unstructured":"Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120(12):1644\u201350.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1861_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.108.147496","volume":"329","author":"S Al-Mahmood","year":"2009","unstructured":"Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C, et al. Potent in vivo antiangiogenic effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther. 2009;329(2):496\u2013504.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1861_CR7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1167\/iovs.11-9064","volume":"53","author":"F Cloutier","year":"2012","unstructured":"Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, et al. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci. 2012;53(3):1195\u2013203.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"1861_CR8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.04.016","volume":"116","author":"C Cursiefen","year":"2009","unstructured":"Cursiefen C, Bock F, Horn FK, Kruse FE, Seitz B, et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology. 2009;116(9):1630\u20137.","journal-title":"Ophthalmology"},{"issue":"9","key":"1861_CR9","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","volume":"121","author":"C Cursiefen","year":"2014","unstructured":"Cursiefen C, Viaud E, Bock F, Geudelin B, Ferry A, et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study. Ophthalmology. 2014;121(9):1683\u201392.","journal-title":"Ophthalmology"},{"issue":"10","key":"1861_CR10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0161-6420(95)30848-2","volume":"102","author":"CRVO Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion","year":"1995","unstructured":"CRVO Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. 1995;102(10):1434\u201344.","journal-title":"Ophthalmology"},{"key":"1861_CR11","doi-asserted-by":"crossref","unstructured":"Esponda-Lammoglia C, Castaneda-D\u00edez R, Garc\u00eda-Aguirre G, Albis-Donado O, Jim\u00e9nez-Rom\u00e1n J. In: Dr Shimon Rumelt, editor. Neovascular glaucoma, glaucoma \u2013 basic and clinical aspects. Chapter 15, section 4. InTech Open; 2013.","DOI":"10.5772\/53115"},{"issue":"4","key":"1861_CR12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","volume":"115","author":"CRVO Study Group","year":"1997","unstructured":"CRVO Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115(4):486\u201391.","journal-title":"Arch Ophthalmol."},{"issue":"6","key":"1861_CR13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0181-5512(07)89662-8","volume":"30","author":"A Bellotti","year":"2007","unstructured":"Bellotti A, Labbe A, Fayol N, El Mahtoufi A, Baudouin C. OCT and neovascular glaucoma. J Fr Ophthalmol. 2007;30(6):586\u201391.","journal-title":"J Fr Ophthalmol"},{"issue":"34","key":"1861_CR14","doi-asserted-by":"crossref","first-page":"31964","DOI":"10.1074\/jbc.M303314200","volume":"278","author":"ZY Jiang","year":"2003","unstructured":"Jiang ZY, He Z, King BL, Kuroki T, Opland DM, et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem. 2003;278(34):31964\u201371.","journal-title":"J Biol Chem"},{"issue":"1","key":"1861_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10792-007-9105-2","volume":"28","author":"F Batioglu","year":"2008","unstructured":"Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008;28(1):59\u201361.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"1861_CR16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3928\/1542-8877-20060301-11","volume":"37","author":"MY Kahook","year":"2006","unstructured":"Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37(2):144\u20136.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"9","key":"1861_CR17","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.ophtha.2008.02.026","volume":"115","author":"T Wakabayashi","year":"2008","unstructured":"Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571\u201380. 1580 e1-3.","journal-title":"Ophthalmology"},{"issue":"3","key":"1861_CR18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006982-200603000-00017","volume":"26","author":"FH Davidorf","year":"2006","unstructured":"Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26(3):354\u20136.","journal-title":"Retina"},{"issue":"5","key":"1861_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.2008.151472","volume":"93","author":"AL Moraczewski","year":"2009","unstructured":"Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009;93(5):589\u201393.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1861_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12348-015-0069-5","volume":"6","author":"MM Sachdeva","year":"2016","unstructured":"Sachdeva MM, Moshiri A, Leder HA, Scott AW. Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms. J Ophthalmic Inflamm Infect. 2016;6(1):2.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1861_CR21","doi-asserted-by":"publisher","unstructured":"Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2016. doi: 10.1007\/s10792-016-0241-4 .","DOI":"10.1007\/s10792-016-0241-4"},{"issue":"6","key":"1861_CR22","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124\u201333. e1.","journal-title":"Ophthalmology"},{"issue":"4","key":"1861_CR23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00920049","volume":"228","author":"SS Hayreh","year":"1990","unstructured":"Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefes Arch Clin Exp Ophthalmol. 1990;228(4):281\u201396.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1861_CR24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4049\/jimmunol.0903180","volume":"184","author":"T Dietrich","year":"2010","unstructured":"Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010;184(2):535\u20139.","journal-title":"J Immunol"},{"issue":"10","key":"1861_CR25","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1167\/iovs.11-7266","volume":"52","author":"N Boehm","year":"2011","unstructured":"Boehm N, Riechardt AI, Wiegand M, Pfeiffer N, Grus FH. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Invest Ophthalmol Vis Sci. 2011;52(10):7725\u201330.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1861_CR26","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1016\/j.jprot.2012.03.018","volume":"75","author":"S Funke","year":"2012","unstructured":"Funke S, Azimi D, Wolters D, Grus FH, Pfeiffer N. Longitudinal analysis of taurine induced effects on the tear proteome of contact lens wearers and dry eye patients using a RP-RP-Capillary-HPLC-MALDI TOF\/TOF MS approach. J Proteomics. 2012;75(11):3177\u201390.","journal-title":"J Proteomics"},{"issue":"5","key":"1861_CR27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-0031-1273355","volume":"228","author":"FH Grus","year":"2011","unstructured":"Grus FH, Gramlich OW. Autoimmunity and glaucoma. Klin Monbl Augenheilkd. 2011;228(5):439\u201345.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"8","key":"1861_CR28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/prca.200700105","volume":"1","author":"FH Grus","year":"2007","unstructured":"Grus FH, Joachim SC, Pfeiffer N. Proteomics in ocular fluids. Proteomics Clin Appl. 2007;1(8):876\u201388.","journal-title":"Proteomics Clin Appl"},{"issue":"3","key":"1861_CR29","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1167\/iovs.04-0448","volume":"46","author":"FH Grus","year":"2005","unstructured":"Grus FH, Podust VN, Bruns K, Lackner K, Fu S, et al. SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye. Invest Ophthalmol Vis Sci. 2005;46(3):863\u201376.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Pt B","key":"1861_CR30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/978-1-4615-0717-8_70","volume":"506","author":"FH Grus","year":"2002","unstructured":"Grus FH, Sabuncuo P, Herber S, Augustin AJ. Analysis of tear protein patterns for the diagnosis of dry eye. Adv Exp Med Biol. 2002;506(Pt B):1213\u20136.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"1861_CR31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00417-006-0429-9","volume":"245","author":"SC Joachim","year":"2007","unstructured":"Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Grus FH. Analysis of IgG antibody patterns against retinal antigens and antibodies to alpha-crystallin, GFAP, and alpha-enolase in sera of patients with \u2018wet\u2019 age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):619\u201326.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9-10","key":"1861_CR32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/1120672103013009-1003","volume":"13","author":"SC Joachim","year":"2003","unstructured":"Joachim SC, Grus FH, Pfeiffer N. Analysis of autoantibody repertoires in sera of patients with glaucoma. Eur J Ophthalmol. 2003;13(9-10):752\u20138.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1861_CR33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbi.2011.07.241","volume":"26","author":"N Boehm","year":"2012","unstructured":"Boehm N, Wolters D, Thiel U, Lossbrand U, Wiegel N, et al. New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study. Brain Behav Immun. 2012;26(1):96\u2013102.","journal-title":"Brain Behav Immun"},{"issue":"2","key":"1861_CR34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00281-008-0105-8","volume":"30","author":"F Grus","year":"2008","unstructured":"Grus F, Sun D. Immunological mechanisms in glaucoma. Semin Immunopathol. 2008;30(2):121\u20136.","journal-title":"Semin Immunopathol"},{"key":"1861_CR35","first-page":"132","volume":"10","author":"FH Grus","year":"2004","unstructured":"Grus FH, Joachim SC, Hoffmann EM, Pfeiffer N. Complex autoantibody repertoires in patients with glaucoma. Mol Vis. 2004;10:132\u20137.","journal-title":"Mol Vis."},{"issue":"1","key":"1861_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/IJG.0b013e318156a592","volume":"17","author":"FH Grus","year":"2008","unstructured":"Grus FH, Joachim SC, Wuenschig D, Rieck J, Pfeiffer N. Autoimmunity and glaucoma. J Glaucoma. 2008;17(1):79\u201384.","journal-title":"J Glaucoma"},{"key":"1861_CR37","first-page":"1573","volume":"13","author":"SC Joachim","year":"2007","unstructured":"Joachim SC, Wuenschig D, Pfeiffer N, Grus FH. IgG antibody patterns in aqueous humor of patients with primary open angle glaucoma and pseudoexfoliation glaucoma. Mol Vis. 2007;13:1573\u20139.","journal-title":"Mol Vis."},{"issue":"3","key":"1861_CR38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02713680701871157","volume":"33","author":"J Reichelt","year":"2008","unstructured":"Reichelt J, Joachim SC, Pfeiffer N, Grus FH. Analysis of autoantibodies against human retinal antigens in sera of patients with glaucoma and ocular hypertension. Curr Eye Res. 2008;33(3):253\u201361.","journal-title":"Curr Eye Res"},{"issue":"4","key":"1861_CR39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11739-010-0478-2","volume":"6","author":"R Marcucci","year":"2011","unstructured":"Marcucci R, Sofi F, Grifoni E, Sodi A, Prisco D. Retinal vein occlusions: a review for the internist. Intern Emerg Med. 2011;6(4):307\u201314.","journal-title":"Intern Emerg Med"},{"issue":"4","key":"1861_CR40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1442-9071.2006.01212.x","volume":"34","author":"K Gumus","year":"2006","unstructured":"Gumus K, Kadayifcilar S, Eldem B, Saracbasi O, Ozcebe O, et al. Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion? Clin Experiment Ophthalmol. 2006;34(4):305\u201311.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"2","key":"1861_CR41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313\u20139. e1.","journal-title":"Ophthalmology"},{"issue":"4","key":"1861_CR42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.preteyeres.2004.12.001","volume":"24","author":"SS Hayreh","year":"2005","unstructured":"Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24(4):493\u2013519.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"1861_CR43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000068980","volume":"217","author":"SS Hayreh","year":"2003","unstructured":"Hayreh SS. Management of central retinal vein occlusion. Ophthalmologica. 2003;217(3):167\u201388.","journal-title":"Ophthalmologica"},{"key":"1861_CR44","volume-title":"Interim guidelines for management of retinal vein occlusion","author":"The Royal College of Ophthalmologists","year":"2010","unstructured":"The Royal College of Ophthalmologists. Interim guidelines for management of retinal vein occlusion. 2010."},{"issue":"5","key":"1861_CR45","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","volume":"158","author":"Y Ogura","year":"2014","unstructured":"Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158(5):1032\u20138.","journal-title":"Am J Ophthalmol"},{"key":"1861_CR46","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00347-012-2660-6","volume":"109","author":"DDO Gesellschaft","year":"2012","unstructured":"Gesellschaft DDO. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augen\u00e4rzte Deutschlands zur Therapie des Makula\u00f6dems beim retinalen Venenverschluss: Therapeutische Strategien. Der Ophtahlmologe. 2012;109:818\u201331.","journal-title":"Der Ophtahlmologe."},{"issue":"4","key":"1861_CR47","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3129\/i08-076","volume":"43","author":"R Kholdebarin","year":"2008","unstructured":"Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43(4):454\u201361.","journal-title":"Can J Ophthalmol"},{"issue":"Pt 2","key":"1861_CR48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/eye.1998.56","volume":"12","author":"AP Rotchford","year":"1998","unstructured":"Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye (Lond). 1998;12(Pt 2):234\u20136.","journal-title":"Eye (Lond)"},{"key":"1861_CR49","first-page":"29","volume":"105","author":"T Tsai","year":"2007","unstructured":"Tsai T, Robin AL, Smith 3rd JP. An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc. 2007;105:29\u201333. discussion 33\u20135.","journal-title":"Trans Am Ophthalmol Soc"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-1861-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T16:45:40Z","timestamp":1568911540000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-1861-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1861"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-1861-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]},"article-number":"128"}}